Equities research analysts predict that Voyager Therapeutics Inc (NASDAQ:VYGR) will report earnings per share of ($0.76) for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Voyager Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.46) and the lowest estimate coming in at ($0.91). Voyager Therapeutics posted earnings per share of ($0.89) in the same quarter last year, which suggests a positive year over year growth rate of 14.6%. The company is expected to announce its next quarterly earnings report on Thursday, November 1st.
According to Zacks, analysts expect that Voyager Therapeutics will report full-year earnings of ($3.12) per share for the current fiscal year, with EPS estimates ranging from ($3.41) to ($2.43). For the next year, analysts expect that the company will report earnings of ($3.39) per share, with EPS estimates ranging from ($4.29) to ($2.60). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Voyager Therapeutics.
Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Tuesday, August 7th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.13). The company had revenue of $2.58 million during the quarter, compared to analysts’ expectations of $3.00 million. Voyager Therapeutics had a negative return on equity of 80.68% and a negative net margin of 731.88%.
VYGR has been the subject of a number of analyst reports. Morgan Stanley cut Voyager Therapeutics from an “overweight” rating to an “equal” rating in a research report on Monday, September 10th. BidaskClub cut Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, September 8th. Zacks Investment Research upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 11th. BTIG Research restated a “buy” rating and issued a $32.00 price target on shares of Voyager Therapeutics in a research report on Monday, September 10th. Finally, ValuEngine cut Voyager Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 17th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $30.70.
In other Voyager Therapeutics news, Director Glenn Pierce acquired 5,000 shares of the company’s stock in a transaction dated Wednesday, September 12th. The stock was purchased at an average price of $18.44 per share, with a total value of $92,200.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James A. Geraghty acquired 3,000 shares of the company’s stock in a transaction dated Monday, September 10th. The stock was acquired at an average cost of $19.39 per share, with a total value of $58,170.00. Following the purchase, the director now owns 76,588 shares of the company’s stock, valued at $1,485,041.32. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 11,000 shares of company stock valued at $205,300. Corporate insiders own 33.60% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Northern Trust Corp boosted its stake in shares of Voyager Therapeutics by 33.5% in the second quarter. Northern Trust Corp now owns 267,441 shares of the company’s stock worth $5,226,000 after acquiring an additional 67,063 shares during the period. Trustees of Princeton University bought a new position in Voyager Therapeutics during the second quarter valued at approximately $3,979,000. MetLife Investment Advisors LLC boosted its stake in Voyager Therapeutics by 38.6% during the second quarter. MetLife Investment Advisors LLC now owns 10,649 shares of the company’s stock valued at $208,000 after buying an additional 2,964 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in Voyager Therapeutics by 53.6% during the second quarter. Metropolitan Life Insurance Co. NY now owns 9,048 shares of the company’s stock valued at $177,000 after buying an additional 3,157 shares during the last quarter. Finally, Bank of America Corp DE boosted its stake in Voyager Therapeutics by 207.7% during the second quarter. Bank of America Corp DE now owns 26,046 shares of the company’s stock valued at $509,000 after buying an additional 17,580 shares during the last quarter. 89.64% of the stock is owned by hedge funds and other institutional investors.
VYGR traded up $0.43 during midday trading on Friday, reaching $16.13. The company had a trading volume of 256,414 shares, compared to its average volume of 412,275. The stock has a market cap of $613.69 million, a price-to-earnings ratio of -6.11 and a beta of 2.94. Voyager Therapeutics has a 1 year low of $11.54 and a 1 year high of $31.91.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
See Also: Growth Stocks, What They Are, What They Are Not
Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.